# Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients

> **NCT07631611** · — · COMPLETED · sponsor: **Wenlong Zhong, MD** · enrollment: 938 (actual)

## Conditions studied

- Solid Tumors
- Metastatic Cancer to Liver
- Metastatic Cancer to the Bone
- Metastatic Cancer to the Lung
- Brain Metastasis
- Metastatic Cancers
- Immune Checkpoint Inhibitors
- Tumor Immune Microenvironment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07631611
- **Lead sponsor:** Wenlong Zhong, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-05-20
- **Target enrollment:** 938 (ACTUAL)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631611, "Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07631611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*